Clinical Trial Update: A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 [Phase 1]

View source ↗

Summary

Phase 1 study update for FB418 evaluating safety and tolerability in Parkinson disease and ALS; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis
• Parkinson Disease

Drugs mentioned

• FB418

Snippet

Sponsor: 1ST Biotherapeutics, Inc. | Conditions: Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Status: RECRUITING